Q32 Bio GAAP EPS of -$0.26 beats by $0.07 (QTTB:NASDAQ)

Q32 Bio reported Q3 GAAP EPS of -$0.26, beating estimates by $0.07. The company had $289.6M in cash and cash equivalents as of September 30, 2026, and stated it has sufficient funds for operations.

Original reporting
Published Nov 4, 2026, 12:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$QTTB
Bullish
medium confidence
Mentioned
$QTTB
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$QTTBBullishMed
01

Why it matters

The modest EPS beat provides a small catalyst for short‑term price movement.

02

Market read

Earnings beat offers limited trading opportunity for QTTB.

03

What to watch

Liquidity runway of $289.6 M through Q4 could mitigate short‑term risk.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

Q32 Bio is a Nasdaq‑listed biotech company releasing its quarterly earnings.

Company-level read

Ticker impact

$QTTBBullishMedium confidence
Context

Q32 Bio reported Q3 GAAP EPS of -$0.26, beating expectations by $0.07.

Expected impact

likely slight upward pressure as market prices in the EPS beat

Evidence & confidence

The beat is modest and the company is small‑cap, limiting the magnitude of the move.

Market effects

Minimal impact on the broader biotech sector.

Limited to US small‑cap biotech investors.

Low

Counterpoint

The EPS beat may be outweighed by ongoing cash‑burn concerns.

Key entities

  • Q32 Bio

    Nasdaq‑listed biotech firm reporting Q3 results.

Related articles

$QTTBMedAI 8/10

Q32 Bio Reports Q3 Results; Advances Bempikibart Toward Phase 3 In Alopecia Areata

Q32 Bio (QTTB) reported Q3 2026 results, with R&D expenses rising to $5.1M and net loss increasing to $8.9M. The company presented Phase 2a trial data for bempikibart, showing a 35.3% mean reduction in SALT scores for alopecia areata patients. Q32 Bio plans to initiate a Phase 3 trial in early 2027 and has $289.6M in cash reserves. The stock is currently trading at $8.81, up 0.57%.

$QTTBLow

Q32 Bio 3Q 2026: Net loss $8.9M, EPS $(0.26) — 10-Q Summary

Q32 Bio reported a Q3 2026 net loss of $8.9M, up 20.7% YoY, with EPS loss narrowing to $0.26. The company's bempikibart study showed improved SALT scores and no serious adverse events. Q32 plans regulatory discussions in Q4 2026 and aims to advance bempikibart in early 2027. Akebia will develop ADX-097 after the asset sale.

$QTTBMedAI 8/10

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio reported Q3 2026 results, highlighting positive SIGNAL-AA clinical trial data for bempikibart, a treatment for alopecia areata. The company presented 36-week results and 16-week off-drug findings at EADV Congress, showing durable responses. Q32 Bio plans to initiate a registration-directed program in 1H 2027 and has $289.6M in cash. The company also strengthened its leadership team and expects Phase 3 topline results from the planned program.